China-based CAR-T company Oricell raises $40M more as it looks to go public
Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including a GPC3-targeted autologous CAR-T therapy for a type of liver ...
Original Source
Read the full article at Endpoints →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.